Appendix 1: Finance Charts detailing information included in dashboard

	Monthly Performance	Year To Date Performance	Full Year Forecast Performance

Risk rating

The rating is based on the Monitor methodology

A working capital facility of £11m is assumed for the liquidity calculation

Monthly Performance: N/A

Year To Date Performance

Weighting	Metric Description	Metric Value	Rating	Weighted Value
10%	EBITDA achieved (% of plan)	94.90	4	**0.40**
25%	EBITDA margin (%)	6.27	3	**0.75**
20%	Return on Assets (%)	5.36	4	**0.80**
20%	I&E surplus margin (%)	1.19	3	**0.60**
25%	Liquid ratio (days)	20.75	3	**0.75**
	Overall rating			**3.30**

This is shown as GREEN in the dashboard as it is >= 3

Full Year Forecast Performance

Weighting	Metric Description	Metric Value	Rating	Weighted Value
10%	EBITDA achieved (% of plan)	94.90	4	**0.40**
25%	EBITDA margin (%)	6.27	3	**0.75**
20%	Return on Assets (%)	5.36	4	**0.80**
20%	I&E surplus margin (%)	1.19	3	**0.60**
25%	Liquid ratio (days)	20.75	3	**0.75**
	Overall rating			**3.30**

This is shown as GREEN in the dashboard as it is >= 3

Overall Income & Expenditure

Provisional year-end performance is a surplus of £2m, in line with plan



An in-month I&E surplus of £214k against a planned surplus of £29k giving a positive variance of £186k in the month.

Within this, income is £1.5m above plan (including provision review), expenditure is £1.3m above plan and depreciation is £82k below plan this month due to newly applied negative indexation to fixed assets (see finance report for details)



Provisional year-end performance is a surplus of £1,983k against a planned surplus of £2m giving an adverse variance of £17k.

Within this, income is £4,015k above plan, expenditure is £4,574k above plan, and depreciation is £649k below plan to date



The provisional £2m year-end surplus is primarily due to a number of non-recurrent items such as depreciation savings, release of provisions no longer required and income from PCTs for maternity, reducing waiting lists and incentive payments for meeting and exceeding the ED target.

Performance against SLA - 1 month lag

February over-performance was £740k in-month against SLAs - this is before taking into account additional income targets, e.g. for DTC activity.





SLA income at the end of February was £5.1m above SLA plans (exc. additional targets such as DTC activity)



Forecast overperformance of £5.6m at year-end. However, provisional year-end income position includes provisions for non-payment for follow-up outpatients above SLA target ratios, and for N12 maternity admissions that may require reimbursement.

Cost Improvement Plan



Final March CIP performance is not yet validated



Final March CIP performance is not yet validated



CIP in February was forecast to be £0.7m above plan at year-end (including non-recurrent items), primarily due to including additional income due to Reckitt and Eddington wards being open for the winter. Recurrent CIP was forecast to be £130k above plan.

Cash position against plan

In-Month position for Month 12 (March 2009)

The closing Balance at the end of March was £3.03m which was exactly in line with the previously published forecast.

The 2009/10 rolling cashflow forecast will require remodelling in the light of recently agreed SLAs and work that is currently being undertaken to project activity for the coming year.